1
|
Wang X, Cai L, Wu M, Li G, Zhu Y, Lin X, Yan X, Mo P, Luo H, Fu Z. Real-world experience with anti–programmed cell death protein 1 immunotherapy in patients with esophageal cancer: A retrospective single-center study. Front Oncol 2022; 12:880053. [PMID: 36158675 PMCID: PMC9500415 DOI: 10.3389/fonc.2022.880053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2022] [Accepted: 08/17/2022] [Indexed: 11/13/2022] Open
Abstract
The “real-world” data of programmed cell death protein 1 (PD-1) inhibitors in esophageal cancer (EPC) are still an unmet medical need, including the clinical efficacy and safety. Seventy-seven EPC data were studied retrospectively; the progression-free survival (PFS), risk factors (clinical stages larger than stage II, metastatic sites larger than 2, treatment lines larger than the first line, previous surgical treatment, combined positive score [CPS] expression, etc.), and the safety were analyzed. The median PFS for all patients was 7.2 months, clinical stage > stage II; the number of treatment lines > first line was significantly correlated with prognosis (all P < 0.05). Subgroup analysis showed that the median PFS of patients with clinical stage ≤ II was better; the results were the same for the patients with ≤2 metastatic sites, first-line PD-1 inhibitors, and not previously received radical surgery (all P < 0.05). Meanwhile, the incidence of adverse events (AEs) of varying degrees was 25.97% (20/77) in 20 patients and 6.49% (5/77) of grade 3/4 AEs. The highest AE was myelosuppression (15.58%), followed by liver function injury (7.79%). In addition, ≥2 lines of treatment and >2 metastatic sites predicted poor outcomes for patients with EPC who had failed first-line therapy or progressed with the combined immunotherapy and chemotherapy treatment strategy (all P < 0.05).
Collapse
Affiliation(s)
- Xinpeng Wang
- Department of Radiotherapy, The 900th Hospital of the Joint Logistics Team, Fujian Medical University, Fuzhou, China
- Department of Radiotherapy, Dongfang Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China
| | - Lvjuan Cai
- Department of Radiotherapy, The 900th Hospital of the Joint Logistics Team, Fujian Medical University, Fuzhou, China
- Department of Radiotherapy, Dongfang Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China
| | - Mengjing Wu
- Department of Radiotherapy, The 900th Hospital of the Joint Logistics Team, Fujian Medical University, Fuzhou, China
- Department of Radiotherapy, Dongfang Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China
| | - Guo Li
- Department of Radiotherapy, The 900th Hospital of the Joint Logistics Team, Fujian Medical University, Fuzhou, China
- Department of Radiotherapy, Dongfang Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China
| | - Yunyun Zhu
- Department of Radiotherapy, The 900th Hospital of the Joint Logistics Team, Fujian Medical University, Fuzhou, China
- Department of Radiotherapy, Dongfang Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China
| | - Xinyue Lin
- Department of Radiotherapy, The 900th Hospital of the Joint Logistics Team, Fujian Medical University, Fuzhou, China
- Department of Radiotherapy, Dongfang Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China
| | - Xue Yan
- Department of Radiotherapy, The 900th Hospital of the Joint Logistics Team, Fujian Medical University, Fuzhou, China
- Department of Radiotherapy, Dongfang Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China
| | - Peng Mo
- Department of Radiotherapy, The 900th Hospital of the Joint Logistics Team, Fujian Medical University, Fuzhou, China
- Department of Radiotherapy, Dongfang Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China
| | - Huachun Luo
- Department of Radiotherapy, The 900th Hospital of the Joint Logistics Team, Fujian Medical University, Fuzhou, China
- Department of Radiotherapy, Dongfang Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China
- *Correspondence: Zhichao Fu, ; Huachun Luo,
| | - Zhichao Fu
- Department of Radiotherapy, The 900th Hospital of the Joint Logistics Team, Fujian Medical University, Fuzhou, China
- Department of Radiotherapy, Dongfang Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China
- *Correspondence: Zhichao Fu, ; Huachun Luo,
| |
Collapse
|